Summary of SANUWAVE (SNWV) Q2 2026 Earnings Call

1Key Financial Results and Metrics:

Revenue: $9.7 million, a 3% decrease from $10.1 million in Q2 2025.

UltraMIST System Sales: Declined 34% to $2.3 million from $3.4 million due to market pressures and increased availability of used systems.

UltraMIST Applicator Revenue: Grew 13% year-over-year, reflecting strong demand with unit volume up 27%.

Gross Margin: 76.2%, down from 78.1% year-over-year, primarily due to a shift towards lower-margin consumables.

Operating Loss: $0.3 million, compared to an operating income of $1.4 million in Q2 2025.

Net Loss: $0.7 million, compared to a net income of $0.6 million in the prior year.

Adjusted EBITDA: Positive $1.2 million, down from $3.2 million year-over-year.

2Strategic Updates and Business Highlights:

Applicator Sales: Set a new all-time record for unit volumes and revenues, indicating strong customer confidence in the UltraMIST product.

Market Dynamics: The company is experiencing significant consolidation in the wound care market due to financial pressures on providers, leading to increased sales of used UltraMIST devices.

Regulatory Developments: Positive proposed rule from CMS for 2027 suggests a 14% increase in reimbursement for UltraMIST in hospital outpatient settings, while a separate proposed rule indicates a potential decrease in reimbursement for the physician fee schedule.

3Forward Guidance and Outlook:

Revenue Guidance: SANUWAVE has withdrawn its fiscal year 2026 revenue guidance due to market uncertainties, particularly regarding Medicare reimbursement changes. The company will reassess guidance following the final CMS rule expected in Q4 2026.

4Bad News, Challenges, or Points of Concern:

System Sales Decline: The significant drop in system sales is attributed to the availability of used devices, which has cannibalized new sales.

Market Pressures: The wound care market has faced severe financial strain, with many practitioners going out of business due to reimbursement changes.

Regulatory Risks: Proposed changes to reimbursement rates could negatively impact revenue, with potential declines from $397 to approximately $316 in 2027.

Operating Expenses: Increased operating expenses (up 20% year-over-year) due to investments in headcount and R&D, which may pressure profitability in the near term.

5Notable Q&A Insights:

Customer Segmentation: The breakdown between for-profit and non-profit customers is complex, with many having hybrid models, making precise segmentation challenging.

CMS Reimbursement Calculation: The CEO provided clarity on how the proposed reimbursement rates were calculated, emphasizing the importance of accurate data in the comment period.

Comment Period Engagement: The company plans to actively engage with CMS during the 60-day comment period to advocate for favorable reimbursement rates, with feedback expected around early November. Overall, while SANUWAVE demonstrated strong performance in applicator sales, significant challenges remain in system sales and regulatory environments that could impact future growth and profitability.